Suppr超能文献

保乳术与乳房切除术治疗乳腺癌生存的比较效果再评价:来自国家癌症数据库(NCDB)的倾向评分匹配更新。

A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

机构信息

Gundersen Health System, La Crosse, WI; Gundersen Medical Foundation, La Crosse, WI.

Gundersen Medical Foundation, La Crosse, WI.

出版信息

Clin Breast Cancer. 2019 Jun;19(3):e481-e493. doi: 10.1016/j.clbc.2019.02.006. Epub 2019 Feb 21.

Abstract

BACKGROUND

Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectomy versus mastectomy in the National Cancer Database (NCDB).

PATIENTS AND METHODS

A retrospective cohort of patients with stage I-III breast cancer in the NCDB (2004-2013) was identified. Propensity score matching (PSM), Kaplan-Meier, and multivariate Cox proportional hazards models were used to examine OS by type of surgery.

RESULTS

Of 845,136 patients, 464,052 (54.9%) underwent lumpectomy and 381,084 (45.1%) underwent mastectomy. After PSM, the hazard ratio (HR) and confidence interval (CI) for OS in all patients comparing lumpectomy with mastectomy was 1.02 (CI, 1.00-1.04; P = .002). In patients with stage I, II, and III, they were HR 1.27 (CI, 1.23-1.36; P < .001), HR 0.98 (CI, 0.95-1.01; P = .21), and HR 0.83 (CI, 0.80-0.86; P < .001), respectively. In subgroup analyses of all patients by estrogen receptor (ER) status, they were HR 1.05 (CI, 1.03-1.07; P < .001) and HR 1.00 (CI, 0.96-1.03; P = .65) in ER+ and ER- patients.

CONCLUSION

In our primary model of all stage I-III matched patients, using the most recent NCDB data and the largest observational sample size to date, the OS after mastectomy was not inferior to lumpectomy. This finding can be reassuring to patients and providers. In subgroup analyses, the association between type of surgery and OS differed by cancer stage and hormone receptor status.

摘要

背景

最近的观察性研究令人担忧,因为它们记录了乳房切除术率的上升,同时有十多份报告称保乳术的总生存率(OS)优于乳房切除术。我们的目的是确定在国家癌症数据库(NCDB)中,接受保乳术与乳房切除术的匹配乳腺癌患者的 OS 是否存在差异。

方法

我们在 NCDB 中确定了 2004-2013 年间患有 I-III 期乳腺癌的患者回顾性队列。使用倾向评分匹配(PSM)、Kaplan-Meier 和多变量 Cox 比例风险模型来检查手术类型的 OS。

结果

在 845,136 名患者中,464,052 名(54.9%)接受了保乳术,381,084 名(45.1%)接受了乳房切除术。PSM 后,比较保乳术与乳房切除术的所有患者 OS 的风险比(HR)和置信区间(CI)为 1.02(CI,1.00-1.04;P=0.002)。在 I 期、II 期和 III 期患者中,HR 分别为 1.27(CI,1.23-1.36;P<0.001)、HR 0.98(CI,0.95-1.01;P=0.21)和 HR 0.83(CI,0.80-0.86;P<0.001)。在所有患者的雌激素受体(ER)状态亚组分析中,ER+和 ER-患者的 HR 分别为 1.05(CI,1.03-1.07;P<0.001)和 HR 1.00(CI,0.96-1.03;P=0.65)。

结论

在我们所有 I-III 期匹配患者的主要模型中,使用最新的 NCDB 数据和迄今为止最大的观察性样本量,乳房切除术的 OS 并不劣于保乳术。这一发现可以让患者和提供者感到安心。在亚组分析中,手术类型与 OS 之间的关联因癌症分期和激素受体状态而异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验